Encyclopedia of contested claims
Metformin is being studied as a possible geroscience intervention, but direct evidence that it lengthens life in non-diabetic adults remains limited. Current evidence is mixed, with suggestive biological and observational signals but no completed large randomized lifespan trial in non-diabetic people.
9 reviewing models concluded the claim is mixed by the available evidence.
The Adjudged panel has not yet completed its full review of this claim. This first-pass draft summarizes the main lines of evidence, key uncertainties, and source candidates for later evaluation by reviewers.
Metformin is being studied as a possible geroscience intervention, but direct evidence that it lengthens life in non-diabetic adults remains limited. Current evidence is mixed, with suggestive biological and observational signals but no completed large randomized lifespan trial in non-diabetic people.
The claim is that metformin, a long-used medication for type 2 diabetes, can extend lifespan in adults who do not have diabetes. In everyday terms, this means more than improving blood sugar or reducing diabetes complications; it would mean that taking metformin helps non-diabetic adults live longer than they otherwise would.
The claim often appears in discussions of aging biology because metformin affects pathways related to insulin signaling, inflammation, mitochondrial function, and cellular stress responses. These mechanisms are relevant to aging research, but a plausible mechanism is not the same as direct evidence of longer human lifespan.
The population matters. Evidence from people with type 2 diabetes cannot be automatically applied to non-diabetic adults, because the baseline health risks, drug benefits, and possible harms differ.
Direct human evidence in non-diabetic adults is still limited. Small trials have examined metformin’s effects on biomarkers, gene expression, metabolism, or age-related intermediate outcomes, but these studies generally were not designed to determine whether participants lived longer.
Observational studies in people with diabetes have reported associations between metformin use and lower mortality or lower incidence of some age-related diseases compared with some other diabetes treatments. These findings are important for hypothesis generation, but they are affected by treatment-selection differences, diabetes severity, comparator choice, and other confounding factors.
Animal and laboratory research provides a mixed picture. Some model-organism studies suggest metformin can influence aging-related pathways and healthspan-related outcomes, while other studies show smaller effects, context-dependent effects, or no clear lifespan extension depending on species, dose, sex, diet, and study design.
Large geroscience proposals such as TAME have helped focus the field on whether metformin can delay multiple age-related diseases in older adults. However, the key public question here is lifespan extension in non-diabetic adults, and that endpoint has not yet been established by a completed large randomized trial.
A central uncertainty is whether metformin would help, harm, or have little effect in metabolically healthy people. A drug that is beneficial for people with insulin resistance or diabetes may have a different balance of effects in people without those conditions.
Another uncertainty is outcome choice. If metformin delays some age-related diseases but does not increase overall survival, that would be different from extending lifespan. Similarly, changes in biomarkers do not necessarily translate into longer life.
Safety and tolerability also matter for prevention use. Metformin is generally well characterized, but it can cause gastrointestinal side effects, may contribute to vitamin B12 deficiency, and requires caution in people with significant kidney disease or other risk factors.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 70% |
| Mistral Medium 3.5 | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 70% |
| OpenAI GPT-5.4 | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 70% |
| DeepSeek V4 Pro | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 70% |
| Llama 4 Maverick | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 60% |
| Gemini 3.1 Pro | Unclear · 82% | Mixed · 70% | Mixed · 66% | No · 70% |
| Claude Opus 4.7 | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 75% |
| GLM 5.1 | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 85% |
| Kimi K2.6 | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 70% |
| Qwen 3.7 Max | Unclear · 82% | Mixed · 70% | Mixed · 66% | Mixed · 85% |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
There is no conclusive evidence from completed large randomized controlled trials that metformin extends lifespan or all-cause survival in non-diabetic adults, though the ongoing TAME trial is designed to test...
The claim that metformin extends lifespan in non-diabetic adults is currently unsupported by direct, high-quality evidence. No completed large randomized controlled trials (RCTs) have demonstrated increased lif...
Probably not established. The best current answer is that metformin has not been shown to extend lifespan in non-diabetic adults, though it remains biologically plausible and is still under study. Confidence: 0...
The claim that metformin extends lifespan in non-diabetic adults is not supported by direct evidence from completed randomized controlled trials. Confidence in this conclusion is high regarding the absence of d...
Metformin may potentially extend lifespan in non-diabetic adults, but the current evidence is not conclusive. Confidence: 60% The evidence is mixed across different study types. Completed randomized trials have not definitively shown that metformin increases lifespan or all-cause survival in non-diabetic adults. However, observational human studies suggest that metformin users may experience lower mortality or fewer age-related diseases. Animal and mechanistic studies provide a plausible biological basis for metfor...
There is currently no conclusive evidence that metformin extends lifespan in non-diabetic adults, though it is a highly plausible candidate currently under investigation. While preclinical and observational dat...
There is no reliable evidence that metformin extends lifespan in non-diabetic adults. The claim is not established. Confidence: Moderate-to-high that the claim is currently unproven; low confidence about the ul...
Metformin does not currently have proven evidence to extend lifespan in non-diabetic adults. While it is a plausible anti-aging intervention, direct proof of lifespan extension in this specific population is ab...
Metformin has not been demonstrated to extend lifespan in non-diabetic adults, and the evidence required to support that claim does not yet exist. No completed large-scale randomized controlled trial has shown...
No, there is currently no definitive evidence that metformin extends lifespan in non-diabetic adults. While metformin is a leading candidate in geroscience and shows promise for improving healthspan, direct pro...
